Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling

[1]  Jung-Ha Lee,et al.  Molecular identification of Ca(2+)channels in human sperm , 2003, Experimental & Molecular Medicine.

[2]  Hong-Hee Kim,et al.  Lipid rafts are important for the association of RANK and TRAF6 , 2003, Experimental & Molecular Medicine.

[3]  M. Kim,et al.  Glypican‐3 is overexpressed in human hepatocellular carcinoma , 2003, Cancer science.

[4]  S. Ishikawa,et al.  Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling , 2003, International journal of cancer.

[5]  Hoguen Kim,et al.  Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin , 2002, Experimental & Molecular Medicine.

[6]  D. Yoon,et al.  HPV E6 antisense induces apoptosis in CaSki cells via suppression of E6 splicing , 2002, Experimental & Molecular Medicine.

[7]  G. Ronnett,et al.  Plunc, a Member of the Secretory Gland Protein Family, Is Up-regulated in Nasal Respiratory Epithelium after Olfactory Bulbectomy* , 2002, The Journal of Biological Chemistry.

[8]  D. Schlessinger,et al.  Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. , 2002, Developmental biology.

[9]  D. Schlessinger,et al.  Glypican-3 Expression in Wilms Tumor and Hepatoblastoma , 2001, Journal of pediatric hematology/oncology.

[10]  J. Filmus,et al.  Glypican-3 expression is silenced in human breast cancer , 2001, Oncogene.

[11]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[12]  N. Rosenblum,et al.  Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. , 2001, Developmental biology.

[13]  D. Sinnett,et al.  Expression of glypican 3 (GPC3) in embryonal tumors , 2000, International journal of cancer.

[14]  W. Skarnes,et al.  glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. , 2000, Developmental biology.

[15]  S. Jhanwar,et al.  Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma , 2000, Oncogene.

[16]  C. McKerlie,et al.  Glypican-3–Deficient Mice Exhibit Developmental Overgrowth and Some of the Abnormalities Typical of Simpson-Golabi-Behmel Syndrome , 1999, The Journal of cell biology.

[17]  D. Schlessinger,et al.  Frequent silencing of the GPC3 gene in ovarian cancer cell lines. , 1999, Cancer research.

[18]  J. Testa,et al.  OCI-5/GPC3, a Glypican Encoded by a Gene That Is Mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, Induces Apoptosis in a Cell Line–specific Manner , 1998, The Journal of cell biology.

[19]  T. Ludwig,et al.  Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. , 1997, Genes & development.

[20]  Wei Cheng,et al.  Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. , 1997, Cancer research.

[21]  A. Schwartz,et al.  Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. , 1997, The Biochemical journal.

[22]  J. Filmus,et al.  OCI-5/Rat Glypican-3 Binds to Fibroblast Growth Factor-2 but Not to Insulin-like Growth Factor-2* , 1997, The Journal of Biological Chemistry.

[23]  D. Schlessinger,et al.  Simpson-Golabi-Behmel syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. , 1996, American journal of medical genetics.

[24]  D. Schlessinger,et al.  Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome , 1996, Nature Genetics.

[25]  K. Yeo,et al.  Characterization of cell lines established from human hepatocellular carcinoma , 1995, International journal of cancer.